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Background. Vascular endothelial growth factor (VEGF)
regulation of endothelial nitric oxide synthase (eNOS) and
signaling pathways involved have not been well studied in
glomerular endothelial cells (GENCs).
Methods. GENCs grown from tsA58 Immortomice were
used. Immunoblotting and in-cell Western blot analysis were
employed to assess changes in VEGF receptor signaling path-
way and eNOS phosphorylation of ser1177. Immunokinase as-
say and immunoblotting with phosphospecific antibodies were
performed to assess activity of kinases.
Results. VEGF rapidly induced tyrosine phosphorylation of
type 1 and type 2 VEGF receptors. Physical association between
VEGF-receptor 2 (VEGF-R2) and insulin receptor substrate
(IRS-1) and phosphatidylinositol 3′-kinase (PI3K) was induced
by VEGF, which augmented PI3K activity in VEGF-R2 im-
munoprecipitates. VEGF stimulated Akt phosphorylation in
a PI3K-dependent manner. VEGF increased eNOS phospho-
rylation on Ser1177. Activation of eNOS was associated with
nitric oxide generation as measured by medium nitrite con-
tent. Signaling mechanisms involved in VEGF stimulation of
eNOS were explored. VEGF-induced eNOS phosphorylation
was abolished by SU1498, a VEGF-R2 inhibitor, LY294002, a
PI3K inhibitor, and infection of cells with an adenovirus carry-
ing a dominant negative-mutant of Akt, demonstrating the re-
quirement of the VEGF-R2/IRS-1/PI3K/Akt axis for activation
of eNOS. VEGF also activated extracellular signal-regulated
protein kinase (ERK) in a time-dependent manner; and VEGF-
stimulated eNOS phosphorylation on Ser1177 was prevented by
PD098059, an upstream inhibitor of ERK, demonstrating that
ERK was involved in VEGF regulation of eNOS. ERK phos-
phorylation was abolished by LY294002, suggesting ERK was
downstream of PI3K in VEGF-treated GENC.
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Conclusions. Our data demonstrate that in GENC, VEGF
stimulates VEGF-R2/IRS-1/PI3K/Akt axis to regulate eNOS
phosphorylation on Ser1177 in conjunction with the ERK sig-
naling pathway.
Of the constituent cells of the glomerulus, the partic-
ipation of mesangial and epithelial cells in physiologic
and pathologic states has been examined in depth. How-
ever, studies on glomerular endothelial cells (GENCs)
are lacking mainly because of the difficulty in initiating
and maintaining them in culture. This limitation has com-
promised our understanding of the vital part this cell plays
in glomerular physiology and pathology. Endothelial cells
have been extensively studied in other vascular beds. Key
signaling and metabolic pathways in arterial endothelial
cells are altered contributing to endothelial dysfunction
and atherosclerosis. Circulating growth factors and lo-
cally produced humoral agents such as endothelins and
prostaglandins have been identified as important regula-
tors of endothelial integrity and function.
Among growth factors, vascular endothelial growth
factor (VEGF) has emerged as a prime mediator of en-
dothelial cell survival and function. VEGFs are a fam-
ily of polypeptides with diverse functions [1]. The vital
importance of VEGF in integrity of vasculature is un-
derscored by the observation that absence of a single
allele of VEGF is embryonic lethal due to severe derange-
ment in endothelial cell development [2, 3]. In addition
to genesis of endothelium, organization of endothelial
cells into vascular beds is regulated by VEGF and its
cognate VEGF type 1 and type 2 receptors (VEGF-R1
and VEGF-R2). Mice lacking both alleles of VEGF-R1
or VEGF-R2 die in utero due to vascular disorganiza-
tion, and failure of hematopoietic and endothelial devel-
opment, respectively [4, 5]. VEGF is also called vascular
permeability factor as it regulates passage of fluid across
endothelial cell layers [6]. These observations emphasize
the importance of VEGF and its signaling system in the
survival, organization, and function of endothelial cells
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and blood vessels, and they have obvious implications
for glomerular structure and function.
VEGFs are synthesized in several cell compartments
of the nephron, including the visceral epithelial cells of
the glomerulus, and the proximal tubular epithelial cells
[7, 8]. Intense labeling of the renal cortex with labeled
VEGF suggests presence of VEGF receptors in glomeruli
and possibly cortical epithelial cells [9]. In vitro studies
have shown that proximal tubular epithelial cells pos-
sess VEGF receptors and that VEGF regulates impor-
tant metabolic functions of that cell, such as protein
synthesis [10]. Although VEGF receptors have been
identified on the surface of GENCs in vivo [11], to date,
metabolic activities that are under the control of these re-
ceptors have not been identified. Recently, we were able
to grow GENCs from the tsA58 immortalized mice that
carry a temperature sensitive variant of SV40 T antigen
[12]. With the ready availability of GENCs, our aim in
the present study was to investigate a fundamental func-
tion of glomerular endothelium [i.e., expression and ac-
tivation of endothelial nitric oxide synthase (eNOS) by
VEGF]. eNOS is known to regulate glomerular hemody-
namics by generation of nitric oxide; however, the reg-
ulatory pathways that govern its generation have not
been elucidated. Accordingly, we investigated the signal-
ing pathways involved in VEGF-regulation of eNOS in
GENCs.
METHODS
GENCs culture
tsA58 Immortomice, transgenic for the temperature
sensitive SV40 TAg transcribed under interferon-c (INF-
c)–sensitive H-2Kb promoter, were used to isolate and
clone cells from decapsulated glomerular explants; they
have been extensively characterized [12]. For experi-
ments described in this report, GENCs were grown in
Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 5 mmol/L glucose, 25% nutrient mixture F-12 Ham,
and 10% fetal bovine serum (FBS). Monolayers of cells
that were 90% confluent were serum-starved for 24 hours
before experiments were performed. VEGF165, the ma-
jor form of VEGF expressed in the kidney [13], was used
at 20 ng/mL for indicated durations of incubation; this
concentration regulates metabolic functions in renal cells
[10].
Immunoblotting and immunoprecipitation
Cells were washed twice with phosphate buffered
saline and lysed in radioimmunoprecipation assay
(RIPA) buffer [50 mmol/L Tris HCl, pH 7.4, 150 mmol/L
potassium chloride, 1 mmol/L dithiothreitol (DTT),
1 mmol/L ethylenediaminetetraacetic acid (EDTA),
50 mmol/L glycerophosphate, pH 7.5, 50 mmol/L
sodium fluoride, 0.1 mmol/L sodium orthovanadate,
1 mmol/L ethylene glycol-bis (b-aminoethyl ether)-
N,N,N,N′-tetra-acetic acid (EGTA), 2 mmol/L benzami-
dine, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF),
1 lg/mL aprotinin, and 1 lg/mL leupeptin). Cell debris
was removed by centrifugation at 12,000 rpm for 20 min-
utes and concentration of protein was measured using the
Bio-Rad protein reagent (Bio-Rad, Hercules, CA,
USA). Indicated amounts of lysates were separated on
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE), transferred to nitrocellulose mem-
branes and probed with various primary antibodies at
the indicated dilutions followed by incubation with sec-
ondary antibodies that were fluorochrome-coupled or
peroxidase-coupled for detection by Odyssey Infrared
Imaging System (Li-Cor Biosciences, Lincoln, NE, USA)
or enhanced chemiluminescence (ECL) system (Amer-
sham, Piscataway, NJ, USA), respectively. For immuno-
precipitation, 500 lg lysates were incubated with the
indicated antibodies at a 1:100 dilution overnight at 4◦C
with rotation. Immunoprecipitates were then incubated
with a protein A/G agarose slurry for an additional hour
at 4◦C with rotation. Agarose beads were then washed
three times with RIPA buffer, twice with cold phosphate-
buffered saline (PBS), before being used for immunoblot
as described above.
In-cell Western analysis
GENCs were plated in a 96-well plate and grown to
80% confluence, at which time they were incubated in
serum-free medium for 20 hours before being treated as
indicated. Immediately after treatment, cells were incu-
bated in a fixing solution (4% formaldehyde in PBS) for
20 minutes at room temperature. Cells were then perme-
abilized by five washes of 5 minutes each in PBS con-
taining 0.1% Triton X-100. Cells were then blocked by a
90-minute incubation in Li-Cor Odyssey blocking buffer
at room temperature with gentle shaking. The primary
antibodies were added at a concentration of 1:500 and in-
cubated overnight at 4◦C with gentle shaking. Cells were
then washed 5 × 5 minutes each in PBS containing 0.1%
Tween. The secondary antibodies (IRDye800-conjugated
or Alexafluor-conjugated) were added at a concentra-
tion of 1:500 and incubated 1 hour at room tempera-
ture with gentle shaking, after which cells were washed
5 × 5 min in PBS containing 0.1% Tween. The plate was
then scanned using the Odyssey Infrared Imaging System
(169 lm resolution, 2 mm offset, intensity setting of 5 for
both channels). Label intensity was measured by densit-
ometric analysis of the wells.
Phosphatidylinositol 3′-kinase (PI3K) assay
PI3K activity was measured as described in [14]. Briefly,
control and VEGF-treated GENCs were homogenized
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in RIPA buffer. Equal amounts of homogenates (500 lg)
were immunoprecipitated with an antiphosphotyrosine
antibody, then protein A/G agarose slurry was added.
The agarose beads were pelleted, washed, and incubated
with 10 lg phosphatidylinositol for 10 minutes at 25◦C in
PI3K assay buffer containing 20 mmol/L Tris/HCl, pH7.5,
100 mmol/L NaCl, and 0.5 mmol/L EGTA. Following ad-
dition of 20 mmol/L MgCl2 and 5 lCi of 32P-adenosine
triphosphate (ATP) to the assay mixture, reactants were
further incubated for 10 minutes at 25◦C. Reaction was
stopped by adding chloroform/methanol/11.6 N HCl mix-
ture. Reactants were extracted in chloroform and the
organic layer was washed with methanol/1 N HCl mix-
ture. The reaction products were dried, resuspended in
chloroform, separated by silica gel 60 thin layer chro-
matography. Phosphatidylinositol 3 phosphate spots
were visualized by autoradiography.
Infection of GENCs with adenovirus was per-
formed as described in [14]. Briefly, replication-defective
adenovirus vector carrying mouse Akt containing a
serine/threonine-to-alanine mutation at its activation
sites (T308A and S473A) and a hemaglutinin (HA) tag
was used. GENCs were infected with 100 multiplicity of
infection (MOI) of adenovirus carrying the dominant-
negative mutant of Akt (Ad-DN-Akt) or green fluores-
cent protein (Ad-GFP) for 1 hour at room temperature.
After a 24-hour incubation at 37◦C, cells were stimulated
with VEGF for the indicated time.
Quantification of no release
GENCs were cultured in the 6-well plates in phenol-
free medium. After being serum-starved for 24 hours,
the cells were treated with VEGF for the indicated time.
The amount of nitrite, the stable end product of nitric
oxide oxidation, was used as an indicator of nitric oxide
synthesis, catalyzed by eNOS. Nitrite concentration in the
culture medium was measured using the Griess reaction
with sodium nitrite as a standard, as described [15]. Data
were expressed corrected for protein content.
Statistics
Data from a minimum of three experiments were
expressed as mean ± SEM and analyzed by analysis
of variance (ANOVA) for comparison among multiple
groups using Bonferroni post hoc test analysis (Graph-
Pad Prism; GraphPad Software, San Diego, CA, USA).
P values of < 0.05 were considered significant.
RESULTS
VEGF increases tyrosine phosphorylation of VEGF-R1
and VEGF-R2 in GENCs
We examined whether VEGF regulates tyrosine phos-
phorylation of VEGF-R1 and VEGF-R2, which indi-
IB: PY
IB: VEGF-R1
IB: pY
IB: VEGF-R2
− 2 5 10 15 30 60
Time of treatment with VEGF, minutes
− 5 15 30 60
Time of treatment with VEGF, minutes
IP: VEGFR1
IP: VEGF-R2B
A
Fig. 1. Vascular endothelial growth factor (VEGF) induces tyrosine
phosphorylation in VEGF-receptor 1 (VEGF-R1) and VEGF-receptor
2 (VEGF-R2) in glomerular endothelial cells (GENCs). (A) Equal
amounts of lysates (500 lg) from serum-starved GENCs treated with
or without VEGF (20 ng/mL) for various durations were immunopre-
cipitated (IP) with a specific antibody against VEGF-R1 and run on
a 7.5% gel. Following transfer to nitrocellulose membrane, the mem-
branes were probed with antiphosphotyrosine (PY) antibody (upper
panel) or the immunoprecipitating antibody (lower panel). A repre-
sentative blot from three experiments is shown. (B) Same procedure
was followed as in (A), except that antibody against VEGF-R2 was
employed. A representative blot [immunoblot (IB)] from three exper-
iments is shown.
cates activation of the receptors. Quiescent GENCs were
stimulated with 20 ng/mL VEGF for up to 60 minutes,
and whole cell lysates were used for immunoprecipita-
tion with an antibody against VEGF-R1 or VEGF-R2.
Immune complexes were immunoblotted with an an-
tiphosphotyrosine antibody. VEGF-induced VEGF-R1
tyrosine phosphorylation was biphasic, starting at 2 min-
utes, and peaking between 5 and 10 minutes, almost re-
turning to baseline at 15 and 30 minutes, and showing
a second increment at 60 minutes (Fig. 1A). VEGF-
induced tyrosine phosphorylation of VEGF-R2 was also
rapid, starting at 5 minutes, and remained elevated for 30
minutes (Fig. 1B).
VEGF increases insulin receptor substrate-1 (IRS-1)
tyrosine phosphorylation and its association with
VEGF-R2
We focused on VEGF-R2 for the rest of the studies as
it has been linked to most VEGF-related effects in en-
dothelial cells [1]. IRS-1 is a docking protein that binds
to cytoplasmic domains of several receptors. Following
incubation with VEGF, IRS-1 rapidly associates with
VEGF-R2 in renal epithelial cells and this binding is
required for VEGF induction of protein synthesis [16].
We thus examined whether VEGF promotes IRS-1
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Fig. 2. Vascular endothelial growth factor (VEGF) induces insulin re-
ceptor substrate-1 (IRS-1) tyrosine phosphorylation and promotes as-
sociation between IRS-1 and VEGF-receptor 2 (VEGF-R2). (A) Equal
amounts of lysates (500 lg) from serum-starved glomerular endothelial
cells (GENCs) treated with or without VEGF (20 ng/mL) for vari-
ous durations were immunoprecipitated (IP) with a specific antibody
against IRS-1 and run on a 7.5% gel. Following transfer to nitrocel-
lulose membrane, membranes were probed with antiphosphotyrosine
antibody (upper panel) or the antibody against IRS-1 (lower panel). A
representative blot [immunoblot (IB)] from three experiments is shown.
(B) Equal amounts of lysates (500 lg) from serum-starved GENCs
treated with or without VEGF (20 ng/mL) for various durations were
immunoprecipitated with a specific antibody against VEGF-R2 and run
on a 7.5% gel. Following transfer to nitrocellulose membrane, mem-
branes were probed with antibody against IRS-1 followed by antibody
against VEGF-R2. Increasing density of IRS-1 band shows greater as-
sociation with VEGF-R2 (arrow). NS refers to a nonspecific band. A
representative blot from three experiments is shown. (C) The order
of antibodies used in immunoprecipitation and immunoblotting was
reversed in a separate set of experiments. A representative blot from
three experiments is shown.
association with VEGF-R2 in GENCs. Cell lysates were
used for immunoprecipitation with an antibody against
IRS-1 following addition of VEGF and the immune
complexes were used for Western blot with an antiphos-
photyrosine antibody. Induction of IRS-1 phosphory-
lation was evident at 5 minutes and lasted for up to
30 minutes (Fig. 2A). We next examined whether VEGF
promotes IRS-1 association with VEGF-R2. GENCs
were incubated with VEGF for up to 60 minutes, and
cell lysates were used for immunoprecipitation with an
antibody against VEGF-R2. Immune complexes were
immunoblotted with antibody against IRS-1. VEGF in-
duced a time-dependent physical association between
VEGF-R2 and IRS-1, which lasted for 60 minutes
(Fig. 2B). Qualitatively similar results were obtained
when the order of antibody application was reversed, im-
munoprecipitating with antibody against IRS-1 and im-
munoblotting with antibody against VEGF-R2 (Fig. 2C).
VEGF stimulates PI3K activity in GENCs
In select receptor tyrosine kinase signaling systems
(e.g., insulin receptor), downstream events of receptor
activation depend in part on association of the IRS dock-
ing proteins and SH2 domain–containing proteins. It is
the case for PI3K, which is recruited to receptor tyro-
sine kinase or docking proteins through its p85 regulatory
subunit. VEGF is known to stimulate IRS-1 association
with PI3K and induce activation of the enzyme in renal
epithelial cells [16]. We examined whether VEGF pro-
moted association between p85 and IRS-1 in GENCs.
Cells were incubated with VEGF for up to 60 minutes,
and cell lysates were used for immunoprecipitation with
an antibody against IRS-1. Immune complexes were im-
munoblotted with an antibody against p85 subunit of
PI3K. VEGF induced a rapid association between IRS-1
and p85 that began at 2 minutes and followed a bipha-
sic course for up to 15 minutes, returning to baseline
thereafter (Fig. 3A). To assess the functional relevance
of the association between PI3K and IRS-1, we exam-
ined whether PI3K activity could be detected in phos-
photyrosine immunoprecipitates. Figure 3B shows that
phosphotyrosine-associated PI3K activity increased be-
tween 5 and 15 minutes of VEGF treatment. These data
provide evidence that activated VEGF-R2 recruits the
p85 regulatory subunit of PI3K, probably via IRS-1, re-
sulting in activation of the enzyme.
VEGF-induced Akt phosphorylation requires
PI3K activation
Activation of PI3K results in the formation of phos-
phatidylinositol 3,4,5-trisphosphate (PtdInsP3). Binding
of PtdInsP3 to Akt promotes its translocation to cell
membrane where phosphoinositide-dependent kinase 1
and phosphoinositide-dependent kinase 2 (PDK1 and
PDK2) phosphorylate Akt on Thr308 and Ser473, re-
spectively, leading to its activation. In order to deter-
mine the role of the PI3K/Akt axis in VEGF-induced
phosphorylation of eNOS, we first examined if VEGF in-
duces Akt phosphorylation in GENCs. Although PI3K
is acknowledged to be an upstream regulator of Akt
phosphorylation, Akt can be activated independently of
PI3K, as it has been reported in renal mesangial cells [17].
Immunoblotting of lysates from VEGF-treated GENCs
with an antibody that specifically detects phosphorylated
Ser473 demonstrated that VEGF induced phosphoryla-
tion of Akt within 2 minutes, peaked at 10 minutes (250%
control) (three experiments) (P < 0.01) and waned by
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Fig. 3. Vascular endothelial growth factor (VEGF) promotes associ-
ation between insulin receptor substrate-1 (IRS-1) and phosphatidyli-
nositol 3′-kinase (PI3K). (A) Equal amounts of lysates (500 lg) from
serum-starved glomerular endothelial cells (GENCs) treated with or
without VEGF (20 ng/mL) for various durations were immunoprecip-
itated (IP) with a specific antibody against insulin receptor substrate-1
(IRS-1) and run on a 7.5% gel. Following transfer to nitrocellulose mem-
brane, the membranes were probed with an antibody against p85 sub-
unit of PI3K or the antibody against IRS-1. A representative blot from
three experiments is shown. (B) PI3K activity is increased in the VEGF-
treated GENCs. Equal amounts of lysates (500 lg) from serum-starved
GENCs treated with VEGF for various durations were immunoprecip-
itated with an antiphosphotyrosine antibody. PI3K activity in immune
complexes was measured by adding radiolabeled phosphatidylinositol
(PtdIns), and measuring generation of radioactive PtdInsP3. Phospho-
lipids were separated by thin-layer chromatography, and visualized by
autoradiography. A representative chromatogram from four individual
experiments is shown. Note that the control lane is to the right side of
the figure. NS refers to an artifact.
15 minutes (Fig. 4A). Preincubation with LY294002, a
selective PI3K inhibitor, abolished VEGF-induced Akt
phosphorylation (Fig. 4B), showing that Akt activation
by VEGF is PI3K-dependent.
VEGF induces phosphorylation of eNOS in GENCs
Phosphorylation of eNOS on Ser1177 is required for
its activation. GENCs were incubated with VEGF for
up to 60 minutes, and eNOS phosphorylation was as-
sayed by in-cell Western blot analysis using an antibody
that selectively detects eNOS phosphorylated on Ser1177
(p-eNOS). Actin immunoreactivity was measured in the
same wells to assess employment of equal number of cells,
and results were expressed as p-eNOS/actin ratio. VEGF
stimulated phosphorylation of eNOS in a time depen-
dent manner, with a peak as early as 2 minutes (200%
of control) (four experiments) (P < 0.05 by ANOVA)
followed by a second broader wave that peaked at 30
minutes (470% of control) (four experiments) (P < 0.01
by ANOVA) and waned by 60 minutes (Fig. 5A). In
cells untreated with VEGF, no increase in basal eNOS
phosphorylation was observed. Following phosphoryla-
tion, eNOS uses L-arginine to generate nitric oxide, which
directly regulates hemodynamics of the capillary. Nitric
oxide is promptly converted to nitrite, a stable end prod-
uct. We measured nitrite in the media to test whether
eNOS phosphorylation induced by VEGF in GENCs led
to nitric oxide generation. Medium total nitrite content
corrected to cell protein began to increase at 2 minutes;
it reached significance at 10 minutes (P < 0.01) and re-
mained elevated for 30 minutes (P < 0.05) (Fig. 5B) (four
experiments).
Phosphorylation of eNOS by VEGF requires VEGF-R2
activation
We initiated studies on the signaling mechanisms re-
cruited by VEGF in augmenting eNOS phosphorylation.
As a first step, we examined the need for activation of
VEGF-R2, the receptor that mediates most of VEGF ef-
fects. GENCs were pretreated with SU1498, a selective
VEGF-R2 inhibitor, for 30 minutes before incubation
with VEGF for 30 minutes. eNOS phosphorylation was
measured by in-cell Western blot analysis. Figure 6, upper
panel, shows that VEGF-induced eNOS phosphorylation
was completely inhibited by SU1498 at 30 minutes (four
experiments) (P < 0.01 VEGF vs. SU1498 + VEGF by
ANOVA), but eNOS basal phosphorylation was not af-
fected by SU1498. This was confirmed by immunoblot
analysis of GENC lysates treated with VEGF for 30
minutes (time of maximum eNOS phosphorylation, as
determined by in cell Western blot analysis) with or with-
out preincubation with SU1498 (Fig. 6, lower panel).
These data show that eNOS phosphorylation on Ser1177
requires VEGF-R2 activation. For analyzing changes in
eNOS phosphorylation, we have observed that in-cell
Western blot analysis is more sensitive and lends itself
for better statistical analysis than SDS-PAGE followed by
immunoblotting.
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Fig. 4. Vascular endothelial growth factor
(VEGF) induces phosphorylation of Akt that
is dependent of phosphatidylinositol 3′-kinase
(PI3K) activation. (A) Equal amounts of
lysates (40 lg) from serum-starved glomeru-
lar endothelial cells (GENCs) treated with
VEGF (20 ng/mL) for various durations
were separated on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-
PAGE). Following transfer to nitrocellulose
membrane, the membranes were probed
the antibody against phosphorylated Akt
(p-Akt). The membrane was stripped and
reprobed with an antibody against total Akt
to assess loading. A representative blot (IB)
from three experiments is shown (upper
panel). The lower panel represents densito-
metric analysis of VEGF-induced Akt phos-
phorylation from three individual experi-
ments. Akt phosphorylation is expressed as
percent of control (N = 3) (mean ± SEM).
∗∗P < 0.01 compared to control by analysis
of variance (ANOVA). (B) GENCs were pre-
treated for 30 minutes with selective PI3K in-
hibitor, LY294002 (25 lmol/L), before VEGF
(20 ng/mL) stimulation for 10 minutes. Akt
phosphorylation of was detected by Western
blot as described in (A). A representative blot
from three experiments is shown.
Role of the PI3K/Akt axis in VEGF-induced eNOS
phophorylation
We sought to determine if phosphorylation of eNOS
induced by VEGF was dependent on activation of
PI3K/Akt axis. Preincubation with LY294002 completely
blocked VEGF-stimulated phosphorylation of eNOS at
30 minutes (Fig. 7A, upper panel) (four experiments)
(P < 0.01), but basal phosphorylation of eNOS was not af-
fected by LY294002. An immunoblot performed on cells
stimulated by VEGF for 30 minutes confirmed these find-
ings (Fig. 7A, lower panel), showing that VEGF-induced
eNOS activation is PI3K-dependent.
In order to examine the role of Akt in eNOS activa-
tion by VEGF, the cells were infected with an adenovirus
carrying a dominant-negative construct of Akt (Ad-DN-
Akt) in which the phosphorylation sites of Akt are mu-
tated; an adenovirus carrying GFP (Ad-GFP) was used
as control. VEGF induced phosphorylation of eNOS in
control cells infected with Ad-GFP (Fig. 7B) (three ex-
periments) (P < 0.01 VEGF vs. control by ANOVA),
but not in cells infected with Ad-DN-Akt (P < 0.05 by
ANOVA, Ad-GFP cells + VEGF vs. Ad-DN-Akt cells +
VEGF). Successful expression of Ad-DN-Akt was indi-
cated by detection of HA tag by immunoblotting. Note
that adenoviral infection did not affect basal expression
of eNOS. These data demonstrate that Akt activation is
required for eNOS phosphorylation on Ser1177 stimu-
lated by VEGF.
Role of mitogen-activated protein kinase (MAPK)
signaling pathway in eNOS phosphorylation
The role of extracellular signal-regulated protein ki-
nase (ERK) activation in VEGF-regulation of eNOS is
not clear with conflicting data in the literature. There are
multiple putative sites of ERK-mediated phosphoryla-
tion in eNOS sequence [18], suggesting ERK could be
a potential kinase for eNOS. Accordingly, we examined
the role of ERK in VEGF regulation of eNOS. We first
investigated whether VEGF induces ERK activation in
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Fig. 5. Vascular endothelial growth factor (VEGF) induces phospho-
rylation of endothelial nitric oxide synthase (eNOS) and stimulates ni-
tric oxide generation. (A) Serum-starved glomerular endothelial cells
(GENCs) were treated with 20 ng/mL VEGF for up to 60 minutes. eNOS
phosphorylation on Ser1177 was measured by in-cell Western blot anal-
ysis using a specific antibody as described in the Methods section. Quan-
tification was performed by densitometric analysis of individual wells
and was normalized for cell number in each well by actin immunore-
activity. eNOS phosphorylation is expressed as percentage of control
(four experiments). ∗∗P < 0.01; ∗P < 0.05 compared to control by analy-
sis of variance (ANOVA. (B) Serum-starved GENCs were treated with
20 ng/mL VEGF for up to 60 minutes. The stable end product of ni-
tric oxide, nitrite, was measured in the medium using Griess reaction.
Medium total nitrite content corrected for protein content of the cell
layer was estimated. Composite data from four experiments are shown
relative to control (mean ± SEM). ∗∗P < 0.01; ∗P < 0.05 by analysis of
variance (ANOVA).
GENCs by immunoblotting cell lysates with an antibody
that only recognizes the phosphorylated form of the ki-
nase. In quiescent GENCs, VEGF stimulated ERK phos-
phorylation, which peaked at 5 minutes (180% control)
(three experiments) (P < 0.01 by ANOVA), and lasted
for up to 15 minutes (Fig. 8A). In GENCs pretreated for
30 minutes with 50 lmol/L of PD098059, an inhibitor of
ERK kinase (MEK1/2), the direct upstream activator of
ERK, VEGF failed to induce ERK phosphorylation at 10
minutes (Fig. 8B), indicating MEK was the upstream reg-
ulator of ERK and functional role of ERK in eNOS reg-
ulation in GENCs can be investigated using PD098059.
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Fig. 6. Vascular endothelial growth factor (VEGF) stimulation of en-
dothelial nitric oxide synthase (eNOS) phosphorylation is VEGF-
receptor 2 (VEGF-R2)–dependent. (Upper) Glomerular endothelial
cells (GENCs) were pretreated with a selective VEGF-R2 inhibitor,
SU1498 (10 lmol/L), for 30 minutes before incubation with 20 ng/mL
VEGF for the indicated time. Phosphorylation of eNOS was detected
by in-cell Western blot analysis as previously described. ∗∗P < 0.01,
VEGF vs. control; ##P < 0.01 VEGF vs. SU1498 + VEGF by anal-
ysis of variance (ANOVA). (Lower) Equal amounts of lysates from
GENCs treated with or without VEGF (20 ng/mL) and preincubated
with SU1498 (10 lmol/L) for 30 minutes were immunoblotted (IB)
with phospho-eNOS (p-eNOS) (ser1177)-specific antibody or antibody
against total eNOS. A representative blot from three experiments is
shown.
In order to assess the role of ERK in VEGF-induced
eNOS phosphorylation, GENCs were pretreated with
PD098059 for 30 minutes before stimulation with VEGF
for 30 minutes. Figure 9A, upper panel, shows that
PD098059 prevented VEGF-induced eNOS phosphory-
lation on Ser1177 at 30 minutes (three experiments) (P <
0.01 VEGF vs. PD09859 + VEGF). This result was con-
firmed by immunoblot at 30 minutes of treatment with
VEGF (Fig. 9A, lower panel). These data show that inhi-
bition of the MAPK pathway prevents eNOS phosphory-
lation on Ser1177, indicating ERK also mediates eNOS
phophorylation by VEGF.
As both PI3K and ERK pathways regulated eNOS
phosphorylation, we investigated whether ERK was
downstream of PI3K in GENCs treated with VEGF.
Preincubation of GENCs with LY294002, the selec-
tive PI3K inhibitor abrogated VEGF-induced ERK
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Fig. 7. Endothelial nitric oxide synthase (eNOS) phosphorylation
induced by vascular endothelial growth factor (VEGF) is phosphatidyli-
nositol 3′-kinase (PI3K)-dependent and Akt-dependent. (A) Glomeru-
lar endothelial cells (GENCs) were pretreated for 30 minutes with a
selective PI3K inhibitor, LY294002 (25 lmol/L), before stimulation
with VEGF (20 ng/mL) for 30 minutes. Phosphorylation of eNOS was
detected in-cell Western blot analysis as previously described (upper
panel). ∗∗P < 0.01 VEGF vs. control; ##P < 0.01 VEGF vs. LY294002 +
phosphorylation (Fig. 9B). These data suggest PI3K is
upstream of ERK in VEGF-treated GENCs.
DISCUSSION
Our data demonstrate that VEGF promotes eNOS
phosphorylation on Ser1177 in GENCs, resulting in en-
hanced generation of nitric oxide. Activation of eNOS by
VEGF is dependent on recruitment of VEGF-R2, and
activation of its downstream signaling events, including
tyrosine phosphorylation of IRS-1 and activation of the
PI3K/Akt signaling pathway. Additionally, VEGF also
activates the ERK pathway in a PI3K-dependent manner.
ERK is also involved in the control of eNOS phospho-
rylation on Ser1177. Thus, VEGF activates dual signal-
ing pathways in GENCs (i.e., PI3K/Akt and PI3K/ERK),
which converge on regulation of eNOS phosphoryla-
tion on Ser1177, resulting in activation of the enzyme
(Fig. 10).
VEGF actions are mediated by VEGF-Rs, which func-
tion as tyrosine kinases. Our data show that GENCs
in culture express VEGF-R1 and VEGF-R2, similar
to glomerular endothelial cells in vivo. VEGF induced
a robust and time-dependent phosphorylation of both
VEGF-R1 and VEGF-R2 in GENCs. VEGF-R1 is im-
plicated in macrophage migration and tumor angiogen-
esis [19, 20]. Most of the cellular actions of VEGF in
endothelial cells (e.g., regulation of vascular permeabil-
ity, fenestration of endothelial cells) are predominantly
regulated by VEGF-R2 [21, 22]. Accordingly, we stud-
ied the role of VEGF-R2 in VEGF regulation of eNOS.
VEGF time dependently induced tyrosine phosphoryla-
tion of VEGF-R2 in GENCs. Activated VEGF-R2 bound
to IRS-1 and p85 regulatory component of PI3K. Asso-
ciation of IRS-1 with VEGF-R2 is not well known and
is in agreement with our observations in renal nonen-
dothelial cells [16]. In GENCs, VEGF promoted asso-
ciation between IRS-1 and PI3K via the p85 subunit of
the latter. Our observations cannot determine whether
PI3K binds to both VEGF-R2 and IRS-1 or solely to
VEGF by analysis of variance (ANOVA). Immunoblotting with
phospho-specific and total eNOS antibodies was done in quiescent cells
pre-incubated with LY294002 and incubated with VEGF for 30 minutes.
A representative blot from three experiments is shown (lower panel).
(B) GENCs were infected with an adenovirus carrying the dominant-
negative construct of Akt (Ad-DN-Akt) or an adenovirus carrying
green fluorescent protein (Ad-GFP) (as control) as described in the
Methods section. eNOS phosphorylation on Ser1177 was measured by
immunoblot (IB) using a phospho-specific antibody. Same cell lysates
were assayed by immunoblot with anti-hemaglutinin (HA) antibody to
assess infection efficiency. A representative blot from three indepen-
dent experiments is shown (upper panel). The lower panel represents
composite data of three independent experiments. Phosphorylation of
eNOS is expressed as percentage of control (mean ± SEM). ∗∗P <
0.01 VEGF vs. control; ∗P < 0.05 Ad-GFP + VEGF vs. Ad-DN-Akt +
VEGF by ANOVA.
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Fig. 8. Vascular endothelial growth fac-
tor (VEGF) stimulates extracellular signal-
regulated protein kinase (ERK) phospho-
rylation. (A) Equal amounts of lysates
(40 lg) from serum-starved glomerular en-
dothelial cells (GENCs) treated with or with-
out VEGF (20 ng/mL) for various durations
were separated on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-
PAGE). Following transfer to nitrocellulose
membrane, the membranes were probed the
antibody against phospho-ERK (p-ERK).
The membrane was stripped and reprobed
with an antibody against total ERK to assess
loading. A representative blot [immunoblot
(IB)] from three experiments is shown (up-
per panel). The lower panel represents den-
sitometric analysis of VEGF-induced ERK
phosphorylation from three independent ex-
periments. ERK phosphorylation is expressed
as percentage of control (N = 3) (mean ±
SEM). ∗∗P < 0.01; ∗P < 0.05 compared with
control, by analysis of variance (ANOVA).
(B) GENCs were pretreated for 30 minutes
with a selective ERK kinase (MEK) inhibitor,
PD98059 (50 lmol/L) before VEGF treat-
ment. ERK phosphorylation was assessed by
immunoblot as described earlier. A represen-
tative blot from three experiments is shown.
IRS-1. Recruitment of IRS-1 is likely to serve as a mech-
anism to amplify the signaling cascades downstream of
VEGF-R2. Consonant with VEGF-stimulated binding of
its p85 component with IRS-1, the activity of PI3K in-
creased. VEGF also markedly stimulated the activity of
Akt. As PI3K-independent pathways for Akt activation
have been described in renal mesangial cells [17], whether
prior activation of PI3K was required for Akt activation
by VEGF was evaluated. LY294002, an inhibitor of PI3K,
completely inhibited Akt activation by VEGF suggesting
PI3K activation was needed for VEGF induction of Akt
activity in GENCs.
eNOS was constitutively expressed by the GENCs,
although the basal level of phosphorylation was mini-
mal. VEGF increased ser1177 phosphorylation of eNOS
within minutes and this was accompanied by prompt gen-
eration of nitric oxide. Ser1177 phosphorylation is critical
for eNOS activity [23, 24]. Incubation with LY294002, the
PI3K inhibitor, or expression of dominant-negative mu-
tant of Akt abrogated eNOS phosphorylation induced by
VEGF. These data demonstrate that activation of PI3K-
Akt axis is essential for VEGF activation of eNOS in
GENCs.
We searched for additional signaling regulation of
eNOS phosphorylation by VEGF. VEGF robustly in-
duced activation of ERK in GENCs. There is indirect
evidence that VEGF-induced ERK activation may be im-
portant in some functions of VEGF as upstream regula-
tors of ERK, Raf, and Ras are involved in angiogenesis
[25]. VEGF-induced ERK activation may be important
for endothelial cell proliferation [1], which may be seen in
physiologic and pathologic states of the kidney. Although
ERK is also a serine kinase, there are conflicting reports
on its regulation of ser1177 phosphorylation of eNOS.
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Fig. 9. Phosphorylation of endothelial ni-
tric oxide synthase (eNOS) induced by vas-
cular endothelial growth factor (VEGF) is
extracellular signal-regulated protein kinase
(ERK) kinase (MEK)/ERK dependent. (A)
Glomerular endothelial cells (GENCs) were
pretreated for 30 minutes with PD098059 (50
lmol/L) before VEGF treatment for 30 min-
utes. Phosphorylation of eNOS was detected
by in-cell Western blot analysis as previously
described (upper panel). ∗∗P < 0.01, VEGF
vs. control; ##P < 0.01, VEGF vs. PD098059
+ VEGF by analysis of variance (ANOVA).
Immunoblot (IB) analysis using the same an-
tibody of quiescent cells preincubated with
PD098059 and incubated with VEGF for 30
minutes (lower panel). A representative blot
from three experiments is shown. (B) GENCs
were pretreated for 30 minutes with selec-
tive phosphatidylinositol 3′-kinase (PI3K) in-
hibitor, LY294002 (25 lmol/L), before stimu-
lation with VEGF (20 ng/mL) for 10 minutes.
Phosphorylation of ERK was detected as pre-
viously described in Fig. 8.
Examination of eNOS sequence revealed presence of
consensus sites for ERK phosphorylation. In bovine
aortic endothelial cells treated with bradykinin, ERK
phosphorylates eNOS, likely involving sites other than
ser1177; however, this results in reduction in its activ-
ity [18]. Other investigators have reported that ERK in-
hibitors do not affect nitric oxide generation or nitric
oxide–mediated relaxation of isolated arteries [26, 27].
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Fig. 10. A schematic showing signaling pathways that regulate en-
dothelial growth factor (eNOS) phosphorylation on ser1177 induced by
vascular endothelial growth factor (VEGF) in glomerular endothelial
cells (GENCs). Abbreviations are: IRS-1, insulin receptor substrate-1;
PI 3-kinase, phosphatidylinositol 3′-kinase; ERK, extracellular signal-
regulated protein kinase; NO, nitric oxide.
ERK has been implicated in eNOS activation by high-
density lipoprotein (HDL) which does not seem to in-
volve ser1177 phosphorylation of eNOS [28]. In uterine
arterial endothelial cells, ERK inhibitors have been re-
ported to partially decrease ser1177 phosphorylation of
eNOS, suggesting a role for ERK in this process [29]. As
these data suggested that role of ERK in eNOS phospho-
rylation may vary with endothelial cell origin, we exam-
ined this issue in the GENCs. VEGF robustly induced
phosphorylation of ERK. PD098059, the inhibitor of
MEK, an upstream activator of ERK, abolished VEGF-
induction of ser1177 phosphorylation of eNOS, suggest-
ing a role for ERK. As both PI3K and ERK stimulated
ser1177 phosphorylation of eNOS, we studied their inter-
action. ERK activation was found to be downstream of
PI3K. This is similar to our previous finding in proximal
tubular epithelial cells treated with insulin [30]. These ob-
servations and reports in the literature suggest that data
on eNOS regulation cannot be extrapolated from one en-
dothelial cell type to another. Recent microarray analysis
supports this notion; GENCs from bovine kidney possess
a distinct gene expression profile compared to nonrenal
endothelial cells [31].
Since phosphorylation of eNOS on ser1177 is critical
for activation of the enzyme, convergence of two signal-
ing pathways (MAPK and PI3K) on this residue may have
dual significance. First, the balance between the two sig-
nals may allow fine-tuning of eNOS activation. Addition-
ally, the redundancy of the two signaling pathways en-
sures that eNOS phosphorylation and activation is main-
tained even in situations in which one of them is impaired.
This redundancy will thus ensure access to eNOS activa-
tion and nitric oxide generation.
The functional significance of eNOS activation can be
manifold. eNOS is known to regulate angiogenesis [32,
33]. Some of these effects may be involved in healing
effects of VEGF reported in thrombotic microangiopa-
thy and remnant kidney models of renal disease [34–36].
Nitric oxide generated by eNOS inhibits adhesion of
leukocytes to the endothelium and its dysregulation may
be involved in pathogenesis of glomerulonephritides [37].
VEGF system plays an important role in pregnancy.
Excessive placental production of soluble ectodomain of
VEGF-R1 leads to removal of VEGF from circulation;
the resulting deficiency of VEGF has been implicated
in endotheliolysis seen in preeclampsia [38]. These ob-
servations show that VEGF is needed for glomerular en-
dothelial integrity in normal pregnancy. In contrast to the
salutary effects of VEGF physiologic state of pregnancy
and in inflammatory and remnant kidney models of renal
disease, the growth factor may have a pathogenic role in
diabetic renal disease. Increase in VEGF coincides with
renal cortical growth in mice with type 1 or type 2 diabetes
and in vitro observations suggest VEGF may contribute
to renal hypertrophy by promoting protein synthesis in
proximal tubular epithelial cells [10]. Administration of
anti-VEGF antibodies results in amelioration of protein-
uria and renal growth in animals with type 1 or type 2
diabetes [39, 40]. Additionally, podocyte-specific overex-
pression of VEGF results in collapsing glomerulopathy
[7].
Thus, it appears that the beneficial or harmful effects
of VEGF on the kidney depend on the context of re-
nal injury. Understanding different signaling pathways
employed by VEGF in activation of eNOS may permit
modulation of cellular processes to benefit the kidney and
assist its recovery in pathologic states.
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